Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

Kris, Mark G.; Tonato, Maurizio; Bria, Emilio; Ballatori, Enzo; Espersen, B.T.; Herrstedt, Jørn; Rittenberg, Cynthia N.; Einhorn, Lawrence H.; Grunberg, Steven M.; Saito, Mitsue; Morrow, Gary R.; Hesketh, Paul J.

doi:10.1007/s00520-010-0976-9

Cited by 42 publications

(28 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, not all condition regimens include multiple days' administrations. Indeed, one of the most commonly used regimens, MEL200, provides for a single-day administration of high dose melphalan alone, therefore representing as an ideal test-bed for the study of high-dose therapy effects, whose CINV prophylaxis, should be, in our opinion, the encoded three drugs schedule for HEC regimens (aprepitant, dexamethasone and 5-HT 3 receptor antagonist) [2]. Stem cell infusion is one of the least studied and reported confounding factors.…”

mentioning

confidence: 99%

Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant

Tendas

Sollazzo

Bruno

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

mentioning

confidence: 99%

Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant

Tendas

Sollazzo

Bruno

et al. 2012

Support Care Cancer

View full text Add to dashboard Cite

“…Recently in 2011, an update of consensus recommendations for the prevention of vomiting and nausea following high-emetic risk chemotherapy was published and it was stated that a three-drug combination of a 5-hydroxytryptamine type 3 receptor (5-HT(3)) receptor antagonist, dexamethasone, and aprepitant beginning before chemotherapy and continuing for up to 4 days remains the standard of care (12).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Efficacy of Aprepitant on the Prevention of Chemotherapy-Induced Nausea and Vomiting and Quality of Life with Functional Living Index Emesis

Aksu¹,

Dolasik²,

Ensaroğlu³

et al. 2013

Balkan Med J

View full text Add to dashboard Cite

IntroductionApproxiamately 70-80% of patients receiving chemotherapy experience nausea and/or vomiting. However, emesis, nausea and vomiting significantly affect patients quality of life and can lead to poor compliance with further treatment. They can also cause metabolic imbalances, nutrient depletion, anorexia, decline of the patient's performance status and even withdrawal from curative anticancer treatment. There are several factors affecting the severity and incidence of emesis and vomiting, including type of chemotherapy, dosage, schedule and even individual patient variability (1-3).Vomiting is triggered by impulses to the vomiting center from the chemoreceptor trigger zone, pharynx, gastrointestinal tract and cerebral kortex. The principal neuroreceptors involved in emetic response are dopamine and the seratonin receptors. The others are, corticosteroid, histamine, cannabinoid, acetylcholine and neurokinin-1 (NK-1) receptors. Antiemetics can block different neuronal pathways and exert their effects at different points during emesis course (4).Aprepitant (AP) is a selective NK-1 receptor blocker that blocks the binding of substance -P at the NK-1 receptor in the central nervous system. It differs from the other antiemetics by augmenting the antiemetic activity of the 5-HT3-receptor anatagonists and dexamethasone to inhibit both acute and delayed cisplatin-induced emesis. However, most of the studies, including two phase III studies evaluated the efficieny of aprepitant by self-diary reports and reported only the incidence and severity of emesis. It is also commonly claimed that the nausea and vomiting accompanying cytotoxic chemotherapy have a negative impact on quality of life but there is little empirical data demonstrating that the failure to control postchemotherapy emesis affects aspects of quality of life other than directly related physical symptoms (5, 6). ABSTRACTObjective: Functional Living Index Emesis (FLIE) is developed to evaluate the relationship between emesis and it's effects on patient's daily life and is far more relevant to detect the effectiveness of antiemetic treatment compared with self-diary reports. In this study, the efficacy of oral neurokinin-1 antagonist aprepitant on the prevention of chemotherapy-induced nausea and vomiting and quality of life is evaluated with FLIE.Study Design: Cross sectional study. Material and Methods:Sixty patients with Non-Small Cell Lung Cancer (NSCLC) receiving a chemotherapy regimen consisting of Cisplatin and Docetaxel were evaluated. The patients were prospectively randomized to two groups before the first cycle of chemotherapy. Patients in Group A (31 patients) received 3 daily doses of aprepitant along with oral ondansetron and dexamethasone. The patients in group B (29 patients) received only ondansetron and dexamathasone. The efficacy of both regimens was evaluated by a modified Turkish version of FLIE scale consisting of 18 questions. Results:The number of patients with complete response was 31 in the whole group. Of these 18 patients (58%...

show abstract

“…For the prevention of nausea and vomiting because of HEC, it is recommended the administration of a three-drug regimen containing single dose of aprepitant, 5-HT3RAs and dexamethasone. Palonosetron significantly improved the outcome in delayed phase and is preferred in this regimen (39)(40)(41). A combination of dexamethasone and palonosetron is suggested for standard prophylaxis of acute emesis in MEC and patients treated with AC-based chemotherapy should receive a combination of aprepitant, dexamethasone and 5-HT3RAs.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy-induced nausea and vomiting: update and future options

Pacetti¹

2014

RIO

View full text Add to dashboard Cite

Even though great progress has been made in the control of chemotherapy-induced nausea and vomiting (CINV), more research is still needed. The use of serotonin-5HT3 receptors antagonists(5-HT3RAs) plus dexamethasone has improve the control of CINV and palonosetron, a second-generation 5-HT3RA, appears to be the most effective agents in its class. Aprepitant, the first neurokinin 1 receptor antagonist (NK1RA) has been used effectively as an additive agent to the 5-HT3RAs while rolapitant and netupitant are being evaluated in phase III clinical trials. This review is an update of the current schedules in preventing CINV and considers possible future strategies.KEY WORDS: palonosetron and CINV, NEPA, NK 1 receptor antagonists.

show abstract

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

Cited by 42 publications

References 54 publications

Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant

Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant

Evaluation of the Efficacy of Aprepitant on the Prevention of Chemotherapy-Induced Nausea and Vomiting and Quality of Life with Functional Living Index Emesis

Chemotherapy-induced nausea and vomiting: update and future options

Contact Info

Product

Resources

About